<DOC>
	<DOCNO>NCT01280318</DOCNO>
	<brief_summary>The obvious hypothesis application peri-operative targeted biological agent may counteract tumor growth effect circulate factor improve patient outcome</brief_summary>
	<brief_title>Profile Plasma Growth Factors Before After Head Neck Oncological Non-oncological Surgery</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age 18 year _ histological proven squamous cell carcinoma oral cavity , oropharynx , hypopharinx larynx Patients select primary surgical treatment distant metastasis active second malignancy last 5 year except non melanoma skin cancer carcinoma situ cervix prior concurrent evidence uncontrolled severe pathology preclude administration surgery life expectancy 3 month pregnant nursing ; fertile patient male female , must use effective contraception absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial sign informed consent performance status ECOG 01 Nasopharynx cancer past current malignancy HNSCC performance ECOG status 2 concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol use investigational agent within 4 week prior entry Previous exposure EGFR target therapy know grade hypersensitivity cetuximab legal incapacity limited legal capacity medical psychological condition opiniion investigator would permit patient complete study sign meaningful informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>